GI
DNLI icon

GAMMA Investing’s Denali Therapeutics DNLI Stock Holding History

GAMMA Investing’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.8K Buy
1,549
+121
+8% +$2.49K ﹤0.01% 2453
2026
Q1 		$27.4K Buy
1,428
+466
+48% +$9.27K ﹤0.01% 2549
2025
Q4 		$15.9K Buy
962
+233
+32% +$3.93K ﹤0.01% 2737
2025
Q3 		$10.6K Sell
729
-20
-3% -$287 ﹤0.01% 2855
2025
Q2 		$10.5K Buy
749
+164
+28% +$2.31K ﹤0.01% 2777
2025
Q1 		$7.95K Sell
585
-1,663
-74% -$31.9K ﹤0.01% 2863
2024
Q4 		$45.8K Sell
2,248
-90
-4% -$2.3K ﹤0.01% 1723
2024
Q3 		$68.1K Buy
2,338
+281
+14% +$6.96K 0.01% 1272
2024
Q2 		$47.8K Buy
2,057
+1,847
+880% +$35.5K 0.01% 1225
2024
Q1 		$4.31K Buy
210
+164
+357% +$3.08K ﹤0.01% 2468
2023
Q4 		$736 Buy
+46
New +$911 ﹤0.01% 2879

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GAMMA Investing's DNLI Position: Q2 2026 in Review

GAMMA Investing increased its Denali Therapeutics (DNLI) stake by 8.5% in Q2 2026, buying an estimated $2.49K and bringing the position to 1,549 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2453.

GAMMA Investing first reported a position in DNLI in Q4 2023 and has held it in 11 quarters since. The position peaked at $68.1K in Q3 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • GAMMA Investing held 1,549 shares of Denali Therapeutics worth $39.8K as of Q2 2026.
  • GAMMA Investing bought 121 Denali Therapeutics shares in Q2 2026, an estimated $2.49K.
  • Denali Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2453 holding.
  • GAMMA Investing first reported a position in Denali Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Denali Therapeutics position peaked at $68.1K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.